Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
02 Dec 2023
02 Dec 2023
Historique:
received:
30
05
2023
accepted:
07
11
2023
revised:
26
10
2023
pubmed:
2
12
2023
medline:
2
12
2023
entrez:
1
12
2023
Statut:
aheadofprint
Résumé
Conditioning protocols for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) are being developed continuously to improve their anti-leukemic efficacy and reduce their toxicity. In this study, we compared the conditioning protocol of fludarabine with melphalan 140 mg/m
Identifiants
pubmed: 38040842
doi: 10.1038/s41409-023-02150-w
pii: 10.1038/s41409-023-02150-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Granot N, Storb R. History of hematopoietic cell transplantation: challenges and progress. Haematologica. 2020;105:2716–29.
doi: 10.3324/haematol.2019.245688
pubmed: 33054108
pmcid: 7716373
Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55:1114–25.
doi: 10.1038/s41409-020-0803-y
Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, et al. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020;135:449–52.
doi: 10.1182/blood.2019003662
pubmed: 31826244
pmcid: 8212356
Eapen M, Brazauskas R, Hemmer M, Perez WS, Steinert P, Horowitz MM, et al. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv. 2018;2:2095–103.
doi: 10.1182/bloodadvances.2018021980
pubmed: 30135184
pmcid: 6113615
Baron F, Labopin M, Peniket A, Jindra P, Afanasyev B, Sanz MA, et al. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2015;121:1048–55.
doi: 10.1002/cncr.29163
pubmed: 25424330
Oran B, Ahn KW, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, et al. Fludarabine and melphalan compared with reduced doses of busulfan and fludarabine improve transplantation outcomes in older patients with myelodysplastic syndromes. Transpl Cell Ther. 2021;27:921.e1–921.e10.
doi: 10.1016/j.jtct.2021.08.007
Duque-Afonso J, Finke J, Labopin M, Craddock C, Protheroe R, Kottaridis P, et al. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT acute leukemia working party. Bone Marrow Transpl. 2022;57:1269–76.
doi: 10.1038/s41409-022-01646-1
Wäsch R, Reisser S, Hahn J, Bertz H, Engelhardt M, Kunzmann R, et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transpl. 2000;26:243–50.
doi: 10.1038/sj.bmt.1702512
Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21:1480–4.
doi: 10.1200/JCO.2003.09.110
pubmed: 12697870
Spyridonidis A, Bertz H, Ihorst G, Grüllich C, Finke J. Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies. Blood. 2005;105:4147–8.
doi: 10.1182/blood-2005-01-0196
pubmed: 15867422
Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A, et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood. 2008;112:415–25.
doi: 10.1182/blood-2007-08-104745
pubmed: 18451310
Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, et al. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transpl. 2010;45:429–36.
doi: 10.1038/bmt.2009.189
Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, et al. Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma. 2012;53:901–6.
doi: 10.3109/10428194.2011.631159
pubmed: 21988645
pmcid: 4225703
Majolino I, Davoli M, Carnevalli E, Locasciulli A, Di Bartolomeo P, Scimè R, et al. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma. 2007;48:759–66.
doi: 10.1080/10428190601186150
pubmed: 17454635
Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, Wäsch R, Bertz H, et al. Impact of lung function on bronchiolitis obliterans syndrome and outcome after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning. Biol Blood Marrow Transpl. 2018;24:2277–84.
doi: 10.1016/j.bbmt.2018.06.024
Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, Wäsch R, Bertz H, et al. Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2021;56:110–20.
doi: 10.1038/s41409-020-0986-2
Kanate AS, Nagler A, Savani B. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2:2–4.
doi: 10.2991/chi.d.191207.001
pubmed: 34595436
pmcid: 8432337
Nagler A, Shimoni A Conditioning. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies 2019. 7th edition. Cham (CH): Springer. Chapter 13.
Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Cámara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56:1651–64.
doi: 10.1038/s41409-021-01227-8
pubmed: 33623153
pmcid: 8263343
Saraceni F, Scortechini I, Fiorentini A, Dubbini MV, Mancini G, Federici I, et al. Conditioning regimens for frail patients with acute leukemia undergoing allogeneic stem cell transplant: how to strike gently. Clin Hematol Int. 2021;3:153–60.
doi: 10.2991/chi.k.210731.001
pubmed: 34938987
pmcid: 8690700
Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16:1525–36.
doi: 10.1016/S1470-2045(15)00200-4
pubmed: 26429297
Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transpl. 2002;8:468–76.
doi: 10.1053/bbmt.2002.v8.pm12374451
de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857–64.
doi: 10.1182/blood-2004-02-0414
pubmed: 15073038
Beelen DW, Stelljes M, Reményi P, Wagner-Drouet EM, Dreger P, Bethge W, et al. Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial. Am J Hematol. 2022;97:1023–34.
doi: 10.1002/ajh.26620
pubmed: 35617104
Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia. 2007;21:2109–16.
doi: 10.1038/sj.leu.2404886
pubmed: 17690701
Bernardo ME, Zecca M, Piras E, Vacca A, Giorgiani G, Cugno C, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol. 2008;143:548–51.
doi: 10.1111/j.1365-2141.2008.07385.x
pubmed: 18986389
Bernardo ME, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A, et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood. 2012;120:473–6.
doi: 10.1182/blood-2012-04-423822
pubmed: 22645178
Finke J, Schmoor C, Stelljes M, Burchert A, Dreger P, Hegenbart U, et al. Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial. Bone Marrow Transpl. 2022;57:1664–70.
doi: 10.1038/s41409-022-01777-5
Sanz J, Boluda JC, Martín C, González M, Ferrá C, Serrano D, et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transpl. 2012;47:1287–93.
doi: 10.1038/bmt.2012.13
Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood. 2013;121:849–57.
doi: 10.1182/blood-2012-08-453399
pubmed: 23165479
Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transpl. 2013;19:117–22.
doi: 10.1016/j.bbmt.2012.08.014
Sora F, Grazia CD, Chiusolo P, Raiola AM, Bregante S, Mordini N. et al. Allogeneic hemopoietic stem cell transplants in patients with Acute Myeloid Leukemia (AML) prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): a retrospective study. Biol Blood Marrow Transpl. 2020;26:698–703.
doi: 10.1016/j.bbmt.2019.12.725
Saraceni F, Labopin M, Hamladji RM, Mufti G, Socié G, Shimoni A, et al. Acute leukemia working party of the European society for Blood and Marrow Transplantation (EBMT). Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. Oncotarget. 2017;9:3379–93.
doi: 10.18632/oncotarget.23273
pubmed: 29423053
pmcid: 5790470
Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, et al. Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol. 2021;39:768–78.
doi: 10.1200/JCO.20.02308
pubmed: 33373276
Marsh RA, Lane A, Mehta PA, Neumeier L, Jodele S, Davies SM, et al. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. Blood. 2016;127:503–12.
doi: 10.1182/blood-2015-07-659672
pubmed: 26644451
Bertz H, Spyridonidis A, Wäsch R, Grüllich C, Egger M, Finke J. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. Biol Blood Marrow Transpl. 2009;15:1563–70.
doi: 10.1016/j.bbmt.2009.08.002